Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of April 16, 2025, Innate Pharma (IPHA) has a market cap of $0.16 billion USD. According to our data, Innate Pharma is ranked No.7189 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Apr 16, 2025 | $0.16 B |
4.80%
|
| Dec 31, 2024 | $0.15 B |
-34.29%
|
| Dec 29, 2023 | $0.23 B |
-24.93%
|
| Dec 30, 2022 | $0.31 B |
-18.20%
|
| Dec 31, 2021 | $0.38 B |
11.49%
|
| Dec 31, 2020 | $0.34 B |
-36.49%
|
| Dec 31, 2019 | $0.54 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Bristol-Myers Squibb
BMY
|
$101.74 B |
-0.001 M
|
USA
|
 Merck
MRK
|
$197.26 B |
0.003 M
|
USA
|
 Pfizer
PFE
|
$127.27 B |
-0.003 M
|
USA
|
 AstraZeneca
AZN
|
$210.42 B |
-0.005 M
|
UK
|
 Novartis
NVS
|
$217.12 B |
0.003 M
|
Switzerland
|
 GlaxoSmithKline
GSK
|
$72.33 B |
-0.002 M
|
UK
|
 Sanofi
SNY
|
$123.58 B |
-0.002 M
|
France
|
 Johnson & Johnson
JNJ
|
$370.20 B |
0.003 M
|
USA
|
 Amgen
AMGN
|
$158.77 B |
0.132 B
|
USA
|
 Regeneron Pharmaceuticals
REGN
|
$60.99 B |
1.014 B
|
USA
|
 Gilead Sciences
GILD
|
$131.74 B |
-0.002 M
|
USA
|
 Biogen
BIIB
|
$17.12 B |
0.000 M
|
USA
|
 Eli Lilly
LLY
|
$679.94 B |
-0.022 M
|
USA
|
 AbbVie
ABBV
|
$312.76 B |
-0.013 M
|
USA
|
| Market Cap | = | IPHA Stock Price | * | IPHA Shares Outstanding |
| = | $1.91 | * | 83.81 M | |
| = | $0.16 B |